1	Article summary	line:	Descri	ptive and	d molecular	epidemiology	y of leishmai	niasis over a	i one-
---	-----------------	-------	--------	-----------	-------------	--------------	---------------	---------------	--------

- 2 year period in the United States
- 3 **Running title:** Molecular detection of leishmaniasis in the United States
- 4 **Keywords:** leishmaniasis; Leishmania; leishmaniasis, cutaneous; leishmaniasis, mucocutaneous;
- 5 leishmaniasis, visceral; polymerase chain reaction; epidemiology
- 6
- 7 **Title:** Windows into leishmaniasis epidemiology in the United States: September 2021 through
- 8 August 2022
- 9

10	Authors: T	Thao T.	Truong,	Karissa	Crawford,	Ichih	Wang-McGuire	e, Kendal	Jensen,	Aisha
----	------------	---------	---------	---------	-----------	-------	--------------	-----------	---------	-------

11 Mushtaq, Nicole A.P. Lieberman, Frederick S. Buckner, Wesley C. Van Voorhis, Brad T.

12 Cookson, Stephen J. Salipante, and Joshua A. Lieberman<sup>#</sup>

- 13
- 14 Affiliations: University of Washington, Seattle, Washington, USA (T. Truong, K. Crawford, I.
- 15 Wang-McGuire, K. Jensen, A. Mushtaq, N. Lieberman, F. Buckner, W. Van Voorhis, B.

16 Cookson, S. Salipante, J. Lieberman)

18	#Corresponding Author: Joshua	A. Lieberman,	joshuaal@uw.edu,	Department o	f Laboratory

- 19 Medicine and Pathology, Box 357110, 1959 NE Pacific St, Seattle, WA 98195 7110
- 20

```
21 ORCIDS: JAL 0000-0002-0376-1337; SJS 0000-0001-8355-6992; TTT 0000-0002-5856-324X,
22 NAPL 0000-0001-9334-8150; WCVV 0000-0001-6141-2015
```

- 23
- 24

#### 25 Abstract

26 Leishmaniasis is a rare disease in the United States, with an estimated annual incidence 27 of dozens of cases occurring primarily in travelers, migrants, and military personnel. True 28 disease incidence is unknown, since leishmaniasis is not a nationally notifiable condition. Here, 29 we describe the results of molecular leishmaniasis over a 1-year interval (September 2021 to 30 August 2022) when our laboratory served as the primary national reference laboratory for 31 molecular diagnosis of civilian leishmaniasis. We tested 218 specimens submitted from 36 states 32 yielding 94/186 (50.5%) positive cases with species or species complex-level identification and 33 18 novel mini-exon alleles. Most species belonged to subgenus Viannia (75.6%) and associated 34 with cutaneous or mucocutaneous disease. Cases were associated with recent travel (18.1%), 35 travel timing unspecified (7.4%), migration (7.4%), remote travel (2.1%), military (1.1%), or 36 unknown history (63.8%). These data illustrate the clinical utility of molecular testing for 37 leishmaniasis and provide unique insight into disease epidemiology.

38

#### 39 Introduction

Leishmania parasites are transmitted to humans by bites from infected phlebotomine 40 41 sandflies. Over 20 Leishmania species are described and cause a wide spectrum of clinical 42 disease in humans. Although leishmaniasis is considered a neglected tropical disease, it is 43 endemic to 98 countries and its worldwide distribution is impacted by human conflict, travel, 44 immigration, and displacement (1). Leishmania species endemic to the Eastern hemisphere have 45 been geographically categorized as "Old World" Leishmania (OWL) whereas those endemic to 46 the Western hemisphere have been termed "New World" Leishmania (NWL) (2). Most human 47 infection is caused by species from one of two subgenera. The New World subgenus Viannia

48 includes L. braziliensis spp. complex and L. guyanensis spp. complex, which cause cutaneous 49 and/or mucocutaneous lesions. Subgenus Leishmania includes Old World L. major, Old World 50 L. tropica spp. complex, and New World L. mexicana spp. complex, which all cause cutaneous 51 leishmaniasis (CL). The Leishmania subgenus additionally includes L. donovani (OWL) and L. 52 infantum (OWL)/L. chagasi (NWL), which are associated with organotropic visceral 53 leishmaniasis (VL), the most fatal clinical manifestation. 54 Diagnostic testing methods include histopathology to visualize intracellular amastigote 55 stage parasites, *in vitro* culturing from lesions, serology, and molecular detection of parasite 56 DNA (3). However, molecular methods are considered most sensitive, and are often most rapid 57 (2–5). The University of Washington (UW) reference laboratory developed and validated a 58 polymerase chain reaction (PCR) and Sanger sequencing assay to detect and identify Leishmania 59 from tissue and body fluid specimens. The approach interrogates the organism's multicopy mini-60 exon gene using primers targeting regions conserved across Leishmania species (6). The 61 amplified region is sufficiently diverse to allow taxonomic determination of species or species 62 complex (6,7). Along with patient immune status, type and severity of clinical disease, and travel 63 history, knowledge of the infecting *Leishmania* species helps determine the risk for 64 mucocutaneous leishmaniasis (MCL), which can impact treatment and management (3). 65 Leishmania has been considered endemic to the United States since 2015, after several reports of autochthonous CL (8-10). Previous studies of *Leishmania* infection epidemiology in 66 67 the U.S. have been limited in scope and often lack species-level identification, comprising 68 surveillance of armed forces members, case reports, and multicenter observational studies (11– 69 13). During September 2021 – July 2022, culture, serology, and molecular testing and 70 identification of *Leishmania* species was temporarily discontinued at the U.S. Centers for

71	Disease Control and Prevention (CDC) as part of an agency-wide pause on clinical testing (14),
72	leaving the UW diagnostic reference laboratory the only service providing molecular Leishmania
73	testing to the general U.S. population during this period (3). This situation offers a unique and
74	relatively unbiased opportunity to examine molecular testing results for patients with suspected
75	leishmaniasis within the United States. Here, we present the largest survey of Leishmania testing
76	in the U.S. performed to date, encompassing 94 positive patient cases with species-level
77	identification from testing specimens from 186 patients submitted over a 1-year period. Our
78	work lends significant insights into descriptive and molecular epidemiology of leishmaniasis in
79	the U.S.

80

#### 81 Materials and Methods

82 Assay Validation

83 We validated a PCR and Sanger sequencing assay targeting the Leishmania mini-exon 84 gene (6) under the CLIA '88 regulatory framework and guidelines established by the Clinical 85 Laboratory Standards Institute. Assay performance was assessed using 7 cultured isolates (axenic 86 promastigote culture) and genomic DNA purchased from the American Type Culture Collection 87 (ATCC 50129); 13 residual clinical specimens positive for *Leishmania* spp. by broad-range 88 fungal PCR performed in our laboratory and/or by culture and molecular analysis at the CDC 89 Parasitic Disease Branch; and 22 residual clinical specimens negative for *Leishmania* spp. but 90 positive for other pathogens (Table S1). DNA extraction, sequence analysis, and case review 91 were performed as previously described (15,16). Specimens were tested in technical duplicate 92 with positive, negative, and inhibition control reactions. Assay performance was fully 93 reproducible across 3 operators.

### 94 Patient Population

95 The study cohort included all patients with leishmania testing performed at the UW 96 Molecular Microbiology clinical diagnostic laboratory between the assay's initial offering on 97 9/1/2021 and 8/31/2022. The CDC referred leishmaniasis testing to the University of 98 Washington from 10/2021 to 7/2022. Acceptable specimen types included fresh and formalin-99 fixed paraffin-embedded (FFPE) tissue, body fluids, buffy coat preparations, and (with 100 laboratory director approval) stain-positive peripheral blood. 101 Demographic and Clinical Information 102 Demographic data including sex, age, state from which specimen was submitted, dates of 103 collection/submission, and specimen description/anatomic site were obtained from the laboratory 104 information system. When available, clinical history, histopathology findings, and travel history 105 were obtained from medical records including physician clinicopathologic consultations. 106 Ethical Approval 107 The study was approved by the UW IRB (STUDY00013877). 108 Data Analysis 109 Data were analyzed in R (version 4.2.1) (17). Maps and figures were generated using 110 usmap, tidyverse, cowplot, and ggtree packages (18–21). "Cases" were defined as unique 111 patients, regardless of the number of specimens tested. Chi-square tests were used to compare 112 categorical variables using GraphPad QuickCalcs (22). 113 Assembled mini-exon sequences were MAFFT aligned in Unipro Ugene v44.0 (23) with 114 published reference sequences representing human-infecting species complexes and curated

115 manually to consolidate mini-exon alleles exhibiting minor length variation. Trees were

generated by IQ-Tree with automatic substitution model optimization (24) and visualized withggtree (25).

118 Data availability

Sequences have been deposited to Genbank (accessions OR026045-OR026086) with
 metadata available in BioSample accessions SAMN35159702 - SAMN35159803 (BioProject
 PRJNA974035). Deidentified, patient-specific molecular data are available upon request with
 appropriate human subject approvals.

123

#### 124 **Results**

125 Assay Validation. We determined assay performance for a PCR and Sanger sequencing 126 assay targeting the Leishmania mini-exon gene (6) using extracted DNA from axenic 127 promastigote culture and residual clinical specimens known to be positive for *Leishmania* spp. or 128 common and/or morphologically similar pathogens (Table S1). The assay's 95% limit of 129 detection (LOD) was established as 1 genome per reaction by testing serial dilutions of purified 130 genomic DNA into testing matrix (Table S2). Sensitivity of testing for DNA extracted from 131 cultured promastigote cell pellets, purified parasite DNA, and patient specimens was 90.5%. 132 Species complex identification was fully concordant with CDC gold-standard testing. Specificity 133 was 100%, with no cross-reactivity with human DNA or other tested pathogens (Table S1). 134 *Testing cohort.* We clinically tested 218 specimens from 186 patients over the one-year 135 period from September 2021 through August 2022. 94 patients (50.5%) had at least 1 specimen 136 positive for Leishmania (Table 1). Specimens were submitted from 36 U.S. states and the 137 territory of Puerto Rico, as well as Quebec, Canada and the Dominican Republic (Figure 1). 138 California, Florida, and Texas submitted the most cases for testing, with corresponding positivity

139 rates of 48.5% (16/33), 50.0% (8/16), and 41.2% (7/17) (Figure 1D). Overall case and specimen 140 positivity rates were 50.5% and 47.7% over the study period (Figure 2A, Table 1, Table 2). The 141 months with the highest case volumes were June, May, and February 2022 (Figure S1). Median 142 test turnaround time was 3.19 days (IQR 1.32 - 3.91) from specimen receipt. 143 Demographics of positive cases. Of patients testing positive for Leishmania, 59/94 144 (62.8%) were aged 20-59 and 19 (20.2%) were under the age of 18, including 11 under age 10 145 years (Table 1, Figure S2). Sixteen patients (17.0%) were over age 60, including 1 patient over 146 80 years (Table 1, Figure S2). More patients with leishmaniasis were male (63.8%) (Table 1). 147 Travel history was unavailable for 60 positive cases (63.8%), while 17 (18.1%) had documented 148 international travel to *Leishmania*-endemic regions within 6 months prior to testing. Two (2.1%)149 cases documented international travel >5 years prior to diagnosis, while 7 (7.4%) noted travel 150 history without specifying timing. Twelve positive cases (12.8%) were associated with travel to 151 Costa Rica (Table S3). There were 7 cases (7.4%) with a history of migration from endemic 152 areas and 1 case (1.1%) from a military service member with L. major. Although we did not 153 receive cases where the possibility of endemic infection was explicitly documented, we noted 2 154 cases positive for L. mexicana spp. complex from Texas, where that species is endemic, although 155 travel information was not provided. 156 Specimen characteristics. Despite expectations for DNA degradation, formalin-fixed 157 paraffin-embedded (FFPE) specimens yielded a higher overall positivity rate than fresh tissue 158 specimens: 60.7% of 107 specimens versus 35.1% of 111 specimens (P < 0.0002, Chi-square

test; Figure 2B, Table 3) (26). Positivity rate was highest (100%) in cases where staining patterns

160 suspicious for intracellular organisms were reported (Table 3). Cases where characteristic

161 Leishmania amastigotes were noted on histopathology had the second highest positivity rate

162	(88.2%) (Table 3). Of the 2 cases that were histopathology positive but negative by molecular
163	testing, one was instead positive for Staphylococcus aureus and the other for Histoplasma
164	capsulatum by additional clinical molecular testing performed in our laboratory.
165	The most commonly involved body sites were skin, representing 86 cases (91.5%),
166	particularly from exposed areas: arms, legs, head, and neck (Figure 3A). Four positive cases
167	(4.3%) were detected from 5 oropharyngeal specimens and identified as <i>L. braziliensis</i> spp.
168	complex, two of which were recurrent infections (Table S4). Only one specimen collected from
169	internal organ sites or body fluids potentially associated with visceral disease tested positive: a
170	paraffin-embedded inguinal lymph node positive for Leishmania donovani spp. complex (Figure
171	3B and 3C).
172	22 patients had multiple specimens submitted. These included 13 positive cases and 9
173	negative cases (Table S4). Of the positive cases, 9 comprised specimen pairs collected less than
174	30 days apart. In 3 cases the initial specimen was positive, but subsequent specimens sent >30
175	days later were negative. One case involved multiple specimens collected 5 months apart that
176	were positive for <i>L. guyanensis</i> spp. complex, having the same mini-exon sequence (Table S4).
177	Two instances showed mini-exon sequence variation across different body sites: one case of L.
178	braziliensis spp. complex in both an epiglottis and pharynx lesion and one case of L. guyanensis
179	spp. complex in both an ear (helix) and shoulder lesion.
180	Leishmania species and molecular epidemiology. Mini-exon sequencing provided
181	adequate resolution (>80% bootstrap) to achieve species complex-level identification (Figure 4,
182	Table 2). Of the 94 positive cases, 71 (75.5%) were subgenus Viannia. 53 (56.4%) were

183 identified as *L. guyanensis* spp. complex, 17 (18.1%) as *L. braziliensis* spp. complex, and 1

184 (1.1%) as *L. lainsoni* spp. complex. Detected sequences included 18 previously unreported mini185 exon alleles (Table S5, BioProject 974035).

186	We observed significant mini-exon sequence conservation within L. braziliensis. Two L
187	braziliensis spp. complex alleles accounted for 10 of 17 cases (Lbr_A-06, Lbr_B-04) and were
188	separated from each other by 3 polymorphisms. Sequence conservation across L. braziliensis and
189	L. peruviana reference strains precluded resolution of these two species with two exceptions.
190	Two mini-exon sequences, Lbr_F and Lbr_G, formed a clade (>95% bootstrap) with "Type 2" L.
191	braziliensis mini-exon reference sequences (KF633199, MHOM/PE/03/LH2511; KF633195,
192	MHOM/CO/90/LEM2216). Travel history was not available for Lbr_F, while Lbr_G had
193	traveled to Peru. These Type 2 braziliensis sequences were detected once each.
194	The two member species of the L. guyanensis spp. complex, L. guyanensis and L.
195	panamensis, had nearly identical previously published mini-exon sequences, precluding
196	identification to the species rank. A single mini-exon allele (Lgu_A-39) accounted for most L.
197	guyanensis spp. complex cases (33/53), including 6 cases with identical sequences recovered in
198	multiple lesions. The second most abundant allele (Lgu-B-07) accounted for 7 cases and was
199	only distinguished from Lgu_A-39 by homopolymer length variation. The next two most
200	abundant alleles (Lgu_C-03, Lgu_D-03) accounted for 6 additional cases.
201	Nine cases (9.6%) were L. mexicana spp. complex and two alleles accounted for 7 of
202	these (Lme_A-04 and Lme_B-03). The detected sequences formed a high-confidence clade with
203	L. mexicana reference sequences (Figure 4). However, the mini-exon sequence (CP040130) from
204	one recently completed, unpublished genome of L. amazonensis, UA301 (GCA_005317125.1)
205	had 100% identity to multiple detected sequences. The UA301 mini-exon sequence thus defies

the otherwise clear separation of *L. mexicana* and *L. amazonensis/L. garnhami* into two clades
that are well-resolved by mini-exon sequences (Figure 4).

208 Fewer cases corresponded to OWL: 10 (10.6%) cases of L. tropica spp. complex and 3 209 (3.2%) L. major, one of which was from a military service member. Other patients positive for 210 OWL include one patient who traveled to Yemen, one who had previously lived in and recently 211 visited Tunisia, and one identified as an Afghan refugee (Table S3). Available clinical history for 212 the one L. donovani spp. complex infection (1.1%) was not sufficient to determine its acquisition 213 and molecular diagnosis could not resolve the organism to the species level. Thus, this case 214 could represent either an infection with Old World species L. donovani or L. infantum, or 215 infection with New World L. chagasi/infantum. 216 Sequences within the *L. tropica* spp. complex included two potential subclades with >80% bootstrap support (Figure 4A-B). The remaining allele (Ltr\_G-01) had 99.75% identity 217 218 over 392 nucleotides to L. killicki (GenBank AY155504) and was derived from a patient who 219 had lived in and recently visited Tunisia. This case was reported to the species rank given the 220 geographic association with *L. killicki* (Figure 4A, Table S3) (27). 221 The distribution of identified species paralleled the travel history in the 34 cases with 222 documented exposures. Of these, 23 (67.6%) had traveled to or from North, Central, or South

America (Table 2, Table S3). There were 7 known migration-related cases, including 6 NWL

infections, comprising five *L. guyanensis* spp. complex; 1 *L. braziliensis* spp. complex. Four

involved patients had traveled from Central and/or South America, while one had immigrated

from West Africa, but did not have explicitly documented travel history to an endemic area. One

227 patient from Afghanistan tested positive for *L. tropica* spp. complex (Table S3, Table S5).

# 229 **Discussion**

250

230	Our work describes molecular reference testing for Leishmania in the general U.S.
231	population during a period where it was otherwise unavailable. This has provided a unique
232	opportunity to compile a comprehensive, 1-year catalog of patient and pathogen characteristics
233	that help approximate the incidence and epidemiology of infections in the U.S. In agreement
234	with prior studies involving U.S. travelers, our case demographics reflect a slight male
235	predominance at 63.8% (12,28-30). Also consistent with previous observations, positive cases
236	were associated with recent travel to Central and South America, particularly Costa Rica, where
237	there is a high incidence of leishmaniasis (Table 1, Table S2) (12,28,29,31). 11.7% of cases in
238	this work were in children younger than 10 and 6.4% in the 10-18 age range, adding to reports of
239	pediatric infection in the U.S. (12,13,29,32,33)
240	Migration-related leishmaniasis has increased globally, but U.Sspecific data has been
241	limited to sporadic case studies (28,34–37). This work identifies 7 cases (7.4% of all positive) of
242	likely migration-related infection originating from multiple continents, highlighting a need for
243	increased clinician awareness in this vulnerable population (Table 1, Table S3). Given that travel
244	histories were not available for most (63.8%) cases, this likely underestimates the true disease
245	burden in this group. Endemic infection with L. mexicana spp. complex has been documented in
246	Texas and Oklahoma, but the provided clinical histories from our cases did not enable us to
247	determine the probability of autochthonous leishmaniasis.
248	CL is the most common clinical manifestation reported in recent U.S. studies. (11–13),
249	and 91.5% of cases in this study were CL. We additionally detected L. braziliensis in 4 patients

251 prior. In contrast, a prior case series and review by Murray et al. reported only 6 documented

with mucosal disease, including two with relapsed MCL acquired during travel several years

252	civilian cases of MCL in the U.S from 1975-2020 (36). Our cohort may be enriched for MCL
253	due to the high prevalence of subgenus Viannia, which accounted for 75% of all cases.
254	Identification to species complexes within subgenus Viannia is clinically informative for
255	treatment and monitoring, due to the associated risk of progression to MCL with most Viannia
256	species (3). Within Viannia, mini-exon sequencing typically lacked resolution beyond the
257	species complex level, particularly L. guyanensis spp. complex (Figure 4). Consistent with prior
258	analyses (6), our assay could distinguish L. braziliensis Type 2 from L. peruviana (Figure 4).
259	Most Type 1 L. braziliensis and L. peruviana couldn't be distinguished; clinically, this may
260	overestimate a patient's risk of developing mucosal disease.
261	Intriguingly, we identified a high-confidence clade of L. braziliensis Type 1 (KF633199,
262	Lbr-B, Lbr-C) that may be separable from L. peruviana and an outlier sequence in L. braziliensis
263	spp. complex (Lbr_H) with 100% identity to the first reported L. braziliensis infection in
264	Suriname (HE610677, Figure 4) (38). These emerging clades suggest additional mini-exon
265	sequences from well-characterized strains could increase molecular diagnostic resolution,
266	particularly in combination with detailed travel history. We note several patients with positive
267	cutaneous specimens who traveled to multiple countries and were consequently at risk for
268	infection from different Leishmania species. In such instances improved species-level
269	identification would more accurately assess risk for progression to mucosal involvement (3).
270	Visceral leishmaniasis cases are rare in the U.S. but have been documented in service
271	members returning from endemic regions, and there are concerns for undetected asymptomatic
272	infection and risk for reactivation in these veterans (11,12,39). In this series, only one case tested
273	positive for L. donovani spp. complex, which is associated with visceral disease and was

274	consistent with our detection in a lymph node. In agreement with previous studies (6) our assay
275	could not distinguish between L. donovani and L. infantum/chagasi.
276	Clinical and laboratory diagnosis of leishmaniasis can be challenging, and molecular
277	methods are considered the most sensitive diagnostic modality (2,3). This work and others have
278	demonstrated the utility of the mini-exon gene as a sensitive, specific, and effective target for
279	distinguishing the major species complexes (6,7,40). Moreover, our assay readily detects
280	infection from a variety of specimen types associated with CL, MCL, and VL, and has
281	demonstrated good performance with FFPE specimens. With rapid turnaround times (~3 days),
282	molecular testing and sequencing can effectively inform patient treatment and management.
283	We found that mini-exon sequencing is sufficient for identification of clinically relevant
284	species complexes, supporting prior work showing that species identification from mini-exon
285	analysis had comparable performance to multilocus sequence typing or single gene target assays
286	(6,40). We successfully resolved <i>L. lainsoni</i> from other <i>Viannia</i> species, which has historically
287	posed technical challenges (6). However, an important limitation is that most closely related
288	species within each of the L. donovani, L. guyanensis, and L. braziliensis species complexes
289	could not be resolved. This challenge is clinically relevant within L. braziliensis spp. complex,
290	given the greater propensity of L. braziliensis for mucocutaneous spread relative to L. peruviana
291	(41). Nevertheless, expanding publicly available mini-exon sequence records may enable more
292	specific identification.
293	We identified 18 previously unreported mini-exon alleles, expanding the diversity of
294	known sequences and highlighting opportunities to improve molecular species identification.
295	Whole-genome sequencing will enable more accurate and specific identification, resolve
296	technical artifacts, and identify co-infections (7). The challenges in resolving species within

complexes and unexpected findings from recently sequenced strains, such as *L. amazonensis*UA301 clading with *L. mexicana* strains, emphasize the evolutionary complexity of *Leishmania*species (42–44).

300 Although illuminating, there are several limitations to this study. First, our estimates of 301 disease burden and the granularity of our demographic data are limited by the incompleteness of 302 clinical information provided to our reference laboratory. This poses particular challenges in 303 interpreting patients with multiple positive specimens, as prolonged PCR positivity does not 304 necessarily reflect treatment failure (45). Second, it is likely that additional civilian cases were 305 not tested at our laboratory, particularly after testing resumed at CDC during July 2022. Third, 306 Leishmania testing remained available for Department of Defense personnel and contractors at 307 the Walter Reed Army Institute of Research (WRAIR) during the study period (46); therefore, 308 the single L. major case we detected in a U.S. armed forces personnel likely underrepresents 309 disease burden. A survey by Stahlman et al documented over 2,000 cases in the U.S. Armed 310 Forces from 2001-2016 but noted significantly fewer cases starting in 2011, with only 11 in 2015 311 (3,11,46). Finally, mini-exon sequence data have inherent limitations. The *Leishmania* mini-exon 312 gene is comprised of 100-200 tandem repeats, which increases the risk of chimeric PCR artifacts 313 (7) and masks low abundance sequence variants. Although our validation studies confirmed this 314 issue did not interfere with the ability to discriminate between different species complexes, we 315 are limited in making more refined phylogenetic inferences that would require more 316 comprehensive whole-genome sequencing data.

Leishmaniasis remains challenging to recognize clinically, and we expect it is still underdiagnosed in the U.S. (2,12,13). Most state public health agencies do not require positive test notification, with the exception of Texas, and suboptimal reporting compliance has been


320	documented (13). Our study demonstrates that molecular testing by mini-exon sequencing
321	provides clinically actionable species-level identification, and when considered in aggregate,
322	suggests a significantly higher annual incidence in the U.S. than previously appreciated. The
323	burden, distribution, and biology of this disease will continue to change with global travel,
324	migration, and climate changes impacting parasite, vector, and host geography (47). This work
325	highlights the role of molecular testing in enabling diagnostic laboratory professionals,
326	providers, and public health agencies to track and appropriately treat this disease.
327	
328	
329	Acknowledgements
330	We are grateful to Stephanie Krieg, MLS(ASCP) and Dr. Dhruba SenGupta for their work
331	establishing clinical assay in the laboratory information system (LIS) and integration with the
332	electronic medical record; Dan Hoogestraat MB(ASCP) for assistance obtaining data from the
333	LIS; and Dr. Noah Hoffman for helpful discussions of phylogenetic analysis. We thank our
334	colleagues at the CDC Parasitic Disease Branch for referring testing to the University of
335	Washington.
336	
337	Biographical Sketch
338	Dr. Truong is a clinical microbiology and molecular microbiology laboratory director at UW
339	Medicine. Her research interests include diagnostic stewardship and evaluating the clinical
340	impact of rapid diagnostic technologies to improve patient care.
341	
342	References

- 343 1.Global leishmaniasis surveillance: 2019–2020, a baseline for the 2030 roadmap [Internet].
- 344 [cited 2022 Sep 13]. Available from: https://www.who.int/publications-detail-redirect/who 345 wer9635-401-419
- Mann S, Frasca K, Scherrer S, Henao-Martínez AF, Newman S, Ramanan P, et al. A Review
   of Leishmaniasis: Current Knowledge and Future Directions. Curr Trop Med Rep.
   2021;8(2):121–32.
- 349 3. Aronson N, Herwaldt BL, Libman M, Pearson R, Lopez-Velez R, Weina P, et al. Diagnosis
  and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases
  Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene
  (ASTMH). Clin Infect Dis. 2016 Dec 15;63(12):e202–64.
- 4. Mathison BA, Bradley BT. Review of the Clinical Presentation, Pathology, Diagnosis, and
   Treatment of Leishmaniasis. Lab Med. 2022 Dec 5;lmac134.
- 5. Goto H, Lindoso JAL. Current diagnosis and treatment of cutaneous and mucocutaneous
  leishmaniasis. Expert Rev Anti Infect Ther. 2010 Apr 1;8(4):419–33.
- 6. Van der Auwera G, Ravel C, Verweij JJ, Bart A, Schönian G, Felger I. Evaluation of Four
  Single-Locus Markers for Leishmania Species Discrimination by Sequencing. J Clin
  Microbiol. 2014 Apr;52(4):1098–104.
- Fernandes O, Murthy VK, Kurath U, Degrave WM, Campbell DA. Mini-exon gene variation
   in human pathogenic Leishmania species. Mol Biochem Parasitol. 1994 Aug 1;66(2):261–71.
- 362 8. World Health Organization. Global leishmaniasis update, 2006–2015: a turning point in
  363 leishmaniasis surveillance. Wkly Epidemiol Rec [Internet]. 2017 Sep 22;92. Available from:
  364 https://www.who.int/publications/i/item/who-wer9238
- 9. Wright NA, Davis LE, Aftergut KS, Parrish CA, Cockerell CJ. Cutaneous leishmaniasis in
  Texas: A northern spread of endemic areas. J Am Acad Dermatol. 2008 Apr 1;58(4):650–2.
- Clarke CF, Bradley KK, Wright JH, Glowicz J. Case report: Emergence of autochthonous
   cutaneous leishmaniasis in northeastern Texas and southeastern Oklahoma. Am J Trop Med
   Hyg. 2013 Jan;88(1):157–61.
- Stahlman S, Williams VF, Taubman SB. Incident diagnoses of leishmaniasis, active and
   reserve components, U.S. Armed Forces, 2001-2016. MSMR. 2017 Feb;24(2):2–7.
- Curtin JM, Aronson NE. Leishmaniasis in the United States: Emerging Issues in a Region
   of Low Endemicity. Microorganisms. 2021 Mar;9(3):578.
- 374 13. McIlwee BE, Weis SE, Hosler GA. Incidence of Endemic Human Cutaneous
  375 Leishmaniasis in the United States. JAMA Dermatol. 2018 Sep 1;154(9):1032–9.

- 376 14. Prevention CC for DC and. CDC Leishmaniasis Resources for Health Professionals
   377 [Internet]. 2022 [cited 2022 Nov 23]. Available from:
- 378 https://www.cdc.gov/parasites/leishmaniasis/health\_professionals/index.html
- Lieberman JA, Bryan A, Mays JA, Stephens K, Kurosawa K, Mathias PC, et al. High
  Clinical Impact of Broad-Range Fungal PCR in Suspected Fungal Sinusitis. J Clin Microbiol.
  2021 Aug 18; JCM0095521.
- McCormick DW, Rassoulian-Barrett SL, Hoogestraat DR, Salipante SJ, SenGupta D,
  Dietrich EA, et al. Bartonella spp. Infections Identified by Molecular Methods, United States.
  Emerg Infect Dis. 2023 Mar;29(3):467–76.
- 385 17. R Core Team. R: A Language and Environment for Statistical Computing [Internet].
  386 Vienna, Austria: R Foundation for Statistical Computing; 2022. Available from: 387 https://www.R-project.org/
- 18. Lorenzo PD. usmap: US Maps Including Alaska and Hawaii [Internet]. 2022 [cited 2022
  Nov 29]. Available from: https://CRAN.R-project.org/package=usmap
- Wickham H, Averick M, Bryan J, Chang W, McGowan LD, François R, et al. Welcome
  to the Tidyverse. J Open Source Softw. 2019 Nov 21;4(43):1686.
- Wilke CO. cowplot: Streamlined Plot Theme and Plot Annotations for "ggplot2"
  [Internet]. 2020 [cited 2022 Nov 29]. Available from: https://CRAN.Rproject.org/package=cowplot
- Wickham H. ggplot2: Elegant Graphics for Data Analysis. [Internet]. Springer-Verlag
  New York; Available from: https://ggplot2.tidyverse.org
- 397 22. GraphPad Software [Internet]. [cited 2023 Feb 4]. Available from:
  398 https://www.graphpad.com/quickcalcs/
- 399 23. Okonechnikov K, Golosova O, Fursov M, the UGENE team. Unipro UGENE: a unified
  bioinformatics toolkit. Bioinformatics. 2012 Apr 15;28(8):1166–7.
- 401 24. Trifinopoulos J, Nguyen LT, von Haeseler A, Minh BQ. W-IQ-TREE: a fast online
  402 phylogenetic tool for maximum likelihood analysis. Nucleic Acids Res. 2016 Jul
  403 8;44(W1):W232–5.
- 404 25. Yu G. Using ggtree to Visualize Data on Tree-Like Structures. Curr Protoc Bioinforma.
   405 2020;69(1):e96.
- 406 26. Guyard A, Boyez A, Pujals A, Robe C, Tran Van Nhieu J, Allory Y, et al. DNA degrades
  407 during storage in formalin-fixed and paraffin-embedded tissue blocks. Virchows Arch Int J
  408 Pathol. 2017 Oct;471(4):491–500.

409 410 411	27. Chaara D, Ravel C, Bañuls AL, Haouas N, Lami P, Talignani L, et al. Evolutionary history of Leishmania killicki (synonymous Leishmania tropica) and taxonomic implications. Parasit Vectors. 2015 Apr 1;8(1):198.
412	28. Boggild AK, Caumes E, Grobusch MP, Schwartz E, Hynes NA, Libman M, et al.
413	Cutaneous and mucocutaneous leishmaniasis in travellers and migrants: a 20-year
414	GeoSentinel Surveillance Network analysis. J Travel Med. 2019 Dec 23;26(8):taz055.
415	<ol> <li>Herwaldt BL, Stokes SL, Juranek DD. American Cutaneous Leishmaniasis in U.S.</li></ol>
416	Travelers. Ann Intern Med. 1993 May 15;118(10):779–84.
417 418 419	30. Melby PC, Kreutzer RD, McMahon-Pratt D, Gam AA, Neva FA. Cutaneous leishmaniasis: review of 59 cases seen at the National Institutes of Health. Clin Infect Dis Off Publ Infect Dis Soc Am. 1992 Dec;15(6):924–37.
420	31. Karimkhani C, Wanga V, Coffeng LE, Naghavi P, Dellavalle RP, Naghavi M. Global
421	burden of cutaneous leishmaniasis: a cross-sectional analysis from the Global Burden of
422	Disease Study 2013. Lancet Infect Dis. 2016 May 1;16(5):584–91.
423	<ol> <li>Douvoyiannis M, Khromachou T, Byers N, Hargreaves J, Murray HW. Cutaneous</li></ol>
424	Leishmaniasis in North Dakota. Clin Infect Dis. 2014 Sep 1;59(5):e73–5.
425	<ol> <li>Ganjaei KG, Lawton K, Gaur S. Cutaneous Leishmaniasis in an American Adolescent</li></ol>
426	Returning From Israel. J Pediatr Infect Dis Soc. 2018 Aug 17;7(3):e178–81.
427 428 429	34. Lemieux A, Lagacé F, Billick K, Ndao M, Yansouni CP, Semret M, et al. Cutaneous leishmaniasis in travellers and migrants: a 10-year case series in a Canadian reference centre for tropical diseases. Can Med Assoc Open Access J. 2022 Apr 1;10(2):E546–53.
430 431	35. Briggs N, Wei BM, Ahuja C, Baker C, Foppiano Palacios C, Lee E, et al. Mucocutaneous Leishmaniasis in a Pregnant Immigrant. Open Forum Infect Dis. 2022 Aug 1;9(8):ofac360.
432	<ol> <li>Murray HW, Eiras DP, Kirkman LA, Chai RL, Caplivski D. Case Report: Mucosal</li></ol>
433	Leishmaniasis in New York City. Am J Trop Med Hyg. 2020 Mar 30;102(6):1319–22.
434	37. Tejura N, Kim E, Dever LL, Chew D. Case Report: Mucocutaneous Leishmaniasis
435	Masquerading as Idiopathic Midline Granulomatous Disease. Am J Trop Med Hyg. 2019 Sep
436	23;101(5):1107–10.
437 438 439	38. Hu RVPF, Kent AD, Adams ER, van der Veer C, Sabajo LOA, Mans DRA, et al. First case of cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis in Suriname. Am J Trop Med Hyg. 2012 May;86(5):825–7.
440	39. Mody RM, Lakhal-Naouar I, Sherwood JE, Koles NL, Shaw D, Bigley DP, et al.
441	Asymptomatic Visceral Leishmania infantum Infection in US Soldiers Deployed to Iraq. Clin
442	Infect Dis. 2019 May 30;68(12):2036–44.


- 443 40. Roelfsema JH, Nozari N, Herremans T, Kortbeek LM, Pinelli E. Evaluation and
  444 improvement of two PCR targets in molecular typing of clinical samples of Leishmania
  445 patients. Exp Parasitol. 2011 Jan 1;127(1):36–41.
- 446
  41. Reyes-Uribe P, Pereira-dos-Santos T, De Jesus JB, Mesquita-Rodrigues C, Arevalo J,
  447
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448
  448<
- 449 2012 Dec;61(4):513–9.
- 450
  42. Species Typing in Dermal Leishmaniasis | Clinical Microbiology Reviews [Internet].
  451
  451 [cited 2022 Oct 4]. Available from: https://journals.asm.org/doi/10.1128/CMR.00104452
  453
  454
  455
  455
  456
  457
  457
  457
  458
  459
  459
  459
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  <l
- 43. Kato H, Gomez EA, Seki C, Furumoto H, Martini-Robles L, Muzzio J, et al. PCR-RFLP
  454 analyses of Leishmania species causing cutaneous and mucocutaneous leishmaniasis revealed
  455 distribution of genetically complex strains with hybrid and mito-nuclear discordance in
  456 Ecuador. PLoS Negl Trop Dis. 2019 May 6;13(5):e0007403.
- 457 44. Kato H, Cáceres AG, Gomez EA, Tabbabi A, Mizushima D, Yamamoto DS, et al.
  458 Prevalence of Genetically Complex Leishmania Strains With Hybrid and Mito-Nuclear
  459 Discordance. Front Cell Infect Microbiol [Internet]. 2021 [cited 2022 Dec 13];11. Available
  460 from: https://www.frontiersin.org/articles/10.3389/fcimb.2021.625001
- 461 45. Mendonça MG, de Brito MEF, Rodrigues EHG, Bandeira V, Jardim ML, Abath FGC.
  462 Persistence of leishmania parasites in scars after clinical cure of American cutaneous
  463 leishmaniasis: is there a sterile cure? J Infect Dis. 2004 Mar 15;189(6):1018–23.
- 464 46. Walter Reed Army Institute of Research (WRAIR) > Collaborate > Leishmania
  465 Diagnostics Laboratory [Internet]. [cited 2022 Nov 30]. Available from: 466 https://wrair.health.mil/Collaborate/Leishmania-Diagnostics-Laboratory/
- 467 47. González C, Wang O, Strutz SE, González-Salazar C, Sánchez-Cordero V, Sarkar S.
  468 Climate change and risk of leishmaniasis in north america: predictions from ecological niche
  469 models of vector and reservoir species. PLoS Negl Trop Dis. 2010 Jan 19;4(1):e585.
- 470 Figures
- 471 Figure 1. Geographic distribution of patients whose specimens were submitted to our
- 472 laboratory for *Leishmania* testing from September 2021 to August 2022.





473


#### Figure 2. Cumulative number of specimens and cases from September 2021 to August 475

#### 476 2022.









# 485 Figure 4. Taxonomic and epidemiologic characteristics of *Leishmania* mini-exon sequences.

#### 488 **Figure legends**

- 489 Figure 1. Geographic distribution of patients whose specimens were submitted to our
- 490 laboratory for *Leishmania* testing from September 2021 to August 2022. Not depicted in this
- 491 figure: 1 case from Quebec, Canada, 1 case from Puerto Rico. 1 case from the Dominican
- 492 Republic was submitted by an institution in Florida. (A) The number of patients tested by each
- 493 state in the U.S. (B) The positivity rate per state during this time period. States shaded in grey
- did not submit any specimens. (C) The number of patients who tested positive for *Leishmania* by
- 495 each state. (D) List of the top 15 states by total test volume.
- 496

#### 497 Figure 2. Cumulative number of specimens and cases from September 2021 to August

- 498 **2022.** Cumulative testing showing (A) total and positive volume of patients and specimens
- 499 during each month and (B) total and positive volume of fresh vs formalin-fixed paraffin-
- 500 embedded specimens during each month.
- 501
- Figure 3. Specimen types submitted for *Leishmania* testing. Number of negative and positive
  specimens submitted from (A) skin and oropharyngeal mucosa, (B) internal organs, and (C) body
  fluids and miscellaneous sites. NOS = Not otherwise specified, RP = retroperitoneal.
- 505

## 506 Figure 4. Taxonomic and epidemiologic characteristics of *Leishmania* mini-exon sequences.

- 507 (A) Detected mini-exon sequences are represented as L, first two letters of species name,
- 508 sequence variant, and number of times detected. The five most abundant mini-exon alleles are

509 marked with arrowheads. Tips are purple triangles. Bootstrap values >95% are indicated as solid

510 black nodes and 85-95% as grey nodes with black borders. Reference sequences are displayed

- 511 with full species name and Genbank accession for mini-exon locus; L. amazonensis strain
- 512 UA301 is indicated by the corresponding mini-exon locus CP040130. X-axis scale is
- 513 substitutions per site. (B) Bars represent defined taxonomic descriptions of subgenus and species
- 514 complex, as well as possible subclades or specific species within each complex as determined by
- 515 mini-exon sequence similarity. (C) Epidemiologic associations, including geography and clinical
- 516 presentation. OWL = Old World *Leishmania*, NWL = New World *Leishmania*.

# 517 Tables

Characteristic	# cases tested	# cases positive	(%) positive by characteristic	(%) positive out of total positive cases (n = 94)
Total tested	186	94	(50.5)	-
Age group				
< 20	30	19	(63.3)	(20.2)
< 10	15	11	(73.3)	(11.7)
20-39	60	34	(56.7)	(36.2)
40-59	57	25	(43.9)	(26.6)
60-79	35	15	(42.9)	(16.0)
>_80	4	1	(25.0)	(1.1)
Sex				
Male	107	60	(56.1)	(63.8)
Female	76	32	(42.1)	(34.0)
Unknown	3	2	(66.7)	(2.1)
Travel history				
Travel history				
Migration	10	7	(70.0)	(7.4)
Travel <u>&lt;</u> 6 months	21	17	(81.0)	(18.1)
Travel >6 months	4	2	(50.0)	(2.1)
Travel, timing not specified	13	7	(53.8)	(7.4)
Military	1	1	(100.0)	(1.1)
No travel history	1	0	(0)	(0)
Unknown	136	60	(44.1)	(63.8)

518 **Table 1. Demographic characteristics of patients with positive** *Leishmania* **PCR results.** 

	320	Table 2. Species identified
<i>Leishmania</i> species (n = 94)	# positive (%) $_{2,1}$	by mini-exon sequencing
Subgenus Viannia		by min exer sequencing
Leishmania braziliensis spp. complex	17 (18.1) 522	
Leishmania guyanensis spp. complex	53 (56.4) 523	
Leishmania lainsoni	1 (1.1) 524	
Subgenus Leishmania	525	
Leishmania donovani spp. complex	1 (1.1) $526 \\ 527$	
Leishmania major	$3 (3.2) \frac{527}{528}$	
Leishmania mexicana spp. complex	9 (9.6) 529	
<i>Leishmania tropica</i> spp. complex <sup>A</sup>	10 (10.6) 530	
		-

531

532

<sup>A</sup> One case was reported as *L. killicki*, a member of the *L. tropica* spp. complex.

534


# 520 **Table 2.** Species identified

	Positive for <i>Leishmania</i> (%)
Specimen type (n = 218)	
Fresh tissue	39/111 (35.1)
FFPE	65/107 (60.7)
Total	104/218 (47.7)
Cases with ulcers or lesions on physical exa	m (n = 186)
Yes	45/68 (66.1)
Unknown	49/118 (41.5)
Cases with histopathological findings	
Amastigotes reported	15/17 (88.2)
Staining suspicious for organisms	12/12 (100.0)
No organisms seen	27/61 (34.4)
Unknown	40/96 (41.7)

# 535 Table 3. Clinical and histopathological correlation with test positivity


# 538 Supplemental Materials


#### 




# 540 Figure S1. Case volume and positivity by month of testing.

### 







562 Figure S2. Age Distribution of Patients Tested for Leishmaniasis.

563 564 Figure S2. Number of patients tested by indicated age range (X-axis). Negative cases are in

gold; positive cases in purple. 565

566

# 568 **Table S1. Test performance and validation**

Specimen number	Specimen type	Reference identification	Leishmania PCR identification	Agreement
1	Cultured strain	L. donovani	<i>L. donovani</i> spp. complex	Yes
2	Cultured strain	L. major	L. major	Yes
3	Cultured strain	L. aethiopica	L. aethiopica	Yes
4	Cultured strain	L. chagasi	<i>L. donovani</i> spp. complex	Yes
5	Cultured strain	L. guyanensis	L. guyanensis	Yes
6	Genomic DNA	L. tropica	L. tropica	Yes
7	Cultured strain	L. panamensis	L. guyanensis/L. panemensis	Yes
8	Cultured strain	L. amazonensis	L. amazonensis	Yes
9	Patient specimen FFPE	L. tropica	L. tropica	Yes
10	Patient specimen FFPE	L. braziliensis	L. braziliensis	Yes
11	Patient specimen FFPE	L. braziliensis	L. braziliensis	Yes
12	Patient specimen FFPE	L. braziliensis	L. braziliensis	Yes
13	Patient specimen FFPE	L. braziliensis	Not detected	No
14	Patient specimen FFPE	L. braziliensis	L. braziliensis	Yes
15	Patient specimen FFPE	L. braziliensis	L. braziliensis	Yes
16	Patient specimen FFPE	L. braziliensis	Not detected	No
17	Patient specimen FFPE	Leishmania sp.	L. chagasi/L. infantum	Yes
18	Patient specimen tissue	Leishmania sp.	L. guyanensis/L. panamensis	Yes
19	Patient specimen tissue	Leishmania sp.	L. guyanensis/L. panamensis	Yes
20	Patient specimen FFPE	Leishmania sp.	L. guyanensis/L. panamensis	Yes
21	Patient specimen tissue	Leishmania sp.	L. braziliensis/L. peruviana	Yes
22	Patient specimen fluid	Pneumocystis jiroveci	Not detected	Yes
23	Patient specimen fluid	Pneumocystis jiroveci	Not detected	Yes

24	Patient specimen tissue	Toxoplasma gondii	Not detected	Yes
25	Patient specimen tissue	Toxoplasma gondii	Not detected	Yes
26	Patient specimen tissue	Histoplasma capsulatum	Not detected	Yes
27	Patient specimen tissue	Histoplasma capsulatum	Not detected	Yes
28	Patient specimen FFPE	Histoplasma capsulatum	Not detected	Yes
29	Patient specimen fluid	Histoplasma capsulatum	Not detected	Yes
30	Patient specimen fluid	Candida albicans	Not detected	Yes
31	Patient specimen FFPE	Candida tropicalis	Not detected	Yes
32	Patient specimen fluid	Candida glabrata	Not detected	Yes
33	Patient specimen tissue	Sporothrix schenckii	Not detected	Yes
34	Patient specimen tissue	Aspergillus fumigatus	Not detected	Yes
35	Patient specimen FFPE	Aspergillus fumigatus	Not detected	Yes
36	Patient specimen tissue	Escherichia coli	Not detected	Yes
37	Patient specimen FFPE	Escherichia coli	Not detected	Yes
38	Patient specimen tissue	Pseudomonas aeruginosa	Not detected	Yes
39	Patient specimen tissue	Pseudomonas aeruginosa	Not detected	Yes
40	Patient specimen fluid	Staphylococcus aureus	Not detected	Yes
41	Patient specimen fluid	Staphylococcus aureus	Not detected	Yes
42	Patient specimen tissue	Streptococcus pneumoniae	Not detected	Yes
43	Patient specimen fluid	Streptococcus pneumoniae	Not detected	Yes

# 572 **Table S2. Limit of detection**

Species	Replicates positive at 1 genome/reaction
L. major	4/4
L. donovani	2/2
L. aethiopica	6/6
L. chagasi	6/6
L. tropica	4/4
L. panamensis	6/6
L. amazonensis	4/4
Total	32/32 (100%)

573

# 574 Table S3. Species identified by travel history

Country	Travel history < 6 mo.	Travel history > 6 mo.	Travel history, timing not specified	Migration	Militar y	Species detected
Central Americ	a					
Belize	1					L. mexicana spp. complex (1)
Costa Rica	9		3			<i>L. guyanensis</i> spp. complex (11) <i>L. braziliensis</i> spp. complex (1)
Guatemala				1		<i>L. braziliensis</i> spp. complex (1)
Panama	1					<i>L. guyanensis</i> spp. complex (1)
Not otherwise specified			1			<i>L. guyanensis</i> spp. complex (1)
North America						
Mexico			1			L. mexicana (1)
South America						
Bolivia		1 <sup>A</sup>				<i>L. braziliensis</i> spp. complex (1)
Ecuador	2			1		<i>L. guyanensis</i> spp. complex (2) <i>L. lainsoni</i> (1)
Peru	1					<i>L. braziliensis</i> spp. complex (1)
Guyana		1				<i>L. braziliensis</i> spp. complex (1)
Venezuela				1		<i>L. guyanensis</i> spp. complex (1)
Middle East						

Afghanistan			1		L. tropica spp. complex (1)
Yemen	1				<i>L. tropica</i> spp. complex (1)
Africa					
Nigeria			1		<i>L. guyanensis</i> spp. complex (1)
Tunisia	1 <sup>B</sup>				L. killicki (1)
Other					
Travel noted, location unknown		1		1	L. major (1) L. braziliensis spp. complex (1)
Multiple endemic countries	1	1	2		<i>L. guyanensis</i> spp. complex (4)

576

<sup>A</sup> Patient had documented infection after traveling in 2016 and had relapse of mucocutaneous

578 leishmaniasis in 2022.

<sup>B</sup> Patient lived in Tunisia prior to coming to the U.S. and developed infection after a recent return
 visit.

581

582

# 583 **Table S4. Repeat testing**

	585
Category	# patients
I. Multiple specimens negative	
a. 30+ days apart	3
b. Within 30 days	6
II. Multiple specimens positive within 30 days	
a. Different sites	4
b. Similar or same site	4
c. Unknown if sites are same or different	1
III. Initial positive specimen, subsequent negative specimen 30+ days later	3
IV. Multiple specimens positive 30+ days apart	1

# 586 Table S5: Metadata for Positive Cases

Study				Location		Mini-Exon	
Number <sup>1</sup>	Age	Sex	Species Identified	Acquired	Anatomic Site	Sequence	Allele Comments
200jB	30-34	Μ	L. braziliensis spp. complex	Not provided	Skin, Arm	Lbr_B-04	
3NY5V	40-44	Μ	L. braziliensis spp. complex	Not provided	Skin, Foot	Lbr_E-01	Previously unreported
3pZcY	15-19	Μ	L. guyanensis spp. complex	Not provided	Skin, Leg	Lgu_F-01	Previously unreported
4AGIK	15-19	Μ	L. mexicana spp. complex	Not provided	Skin, Face	Lme_A-04	
4qXFx	60-64	Μ	L. guyanensis spp. complex	Not provided	Skin, Arm	Lgu_A-39	
4qXFx	60-64	Μ	L. guyanensis spp. complex	Not provided	Skin, Arm	Lgu_A-39	
4Tpmt	65-69	Μ	L. guyanensis spp. complex	Not provided	Skin, Leg	Lgu_A-39	
5d8uv	50-54	Μ	L. guyanensis spp. complex	Not provided	Skin, Arm	Lgu_A-39	
5N4y7	25-29	Μ	L. guyanensis spp. complex	Not provided	Skin, Back	Lgu_E-02	
6DvUz	25-29	Μ	L. guyanensis spp. complex	Not provided	Skin, Hand	Lgu_D-03	
71Qur	30-34	Μ	L. guyanensis spp. complex	Not provided	Skin, Leg	Lgu_B-07	
71E4E	25-29	Μ	L. guyanensis spp. complex	Costa Rica	Skin, Leg	Lgu_A-39	
7nBtA	30-34	Μ	L. guyanensis spp. complex	Not provided	Skin, Face	Lgu_C-03	Previously unreported
9s3Zi	20-24	Μ	L. mexicana spp. complex	Not provided	Skin, Leg	Lme_B-03	
A1UVR	50-54	F	L. guyanensis spp. complex	Costa Rica	Skin, Hand	Lgu_A-39	
aFZBo	50-54	Μ	L. guyanensis spp. complex	Nigeria	Skin, Leg	Lgu_B-07	
				Multiple endemic			
1 DN	15 10	м	<b>.</b>	countries: Costa		1 1 20	
ahPNz	15-19	Μ	L. guyanensis spp. complex	Rica OR BelizeMultiple endemic	Skin, Chest	Lgu_A-39	
				countries: Costa			
ahPNz	15-19	Μ	L. guyanensis spp. complex	Rica OR Belize	Skin, Elbow	Lgu_A-39	
aNewR	5-9	F	L. major	Not provided	Skin, NOS	Lma_B-01	
ASuG7	55-59	М	L. guyanensis spp. complex	Costa Rica	Skin, Leg	Lgu_A-39	
Bb1ZK	50-54	F	L. mexicana spp. complex	Not provided	Skin, Leg	Lme_B-03	

bJ2RQ	65-69	Μ	L. guyanensis spp. complex	Not provided	Skin, NOS	Lgu_C-03	Previously unreported
bVQ6L	5-9	Μ	L. tropica spp. complex	Afghanistan	Skin, Face	Ltr_A-01	Previously unreported
bz3MQ	25-29	Μ	L. guyanensis spp. complex	Costa Rica	Skin, NOS	Lgu_A-39	
cvuHr	40-44	U	L. lainsoni	Ecuador	Skin, Arm	Lla_A-01	Previously unreported
dDNho	< 5	Μ	L. tropica spp. complex	Not provided	Skin, Face	Ltr_H-01	Previously unreported
dl8Uh	< 5	F	L. guyanensis spp. complex	Panama	Skin, Leg	Lgu_A-39	
dOJ9R	35-39	Μ	L. braziliensis	Not provided	Skin, Knee	Lbr_F-01	Type 2 L. braziliensis
DqThk	< 5	F	L. mexicana spp. complex	Not provided	Skin, Face	Lme_D-01	Previously unreported
dxbWJ	20-24	Μ	L. guyanensis spp. complex	Not provided	Skin, Arm	Lgu_A-39	
gdTX9	25-29	Μ	L. tropica spp. complex	Not provided	Skin, Hand	Ltr_B-01	Previously unreported
gSFeb	45-49	Μ	L. guyanensis spp. complex	Costa Rica	Skin, NOS	Lgu_A-39	
hliza	40-44	Μ	L. guyanensis sppp. complex	Not provided	Skin, NOS	Lgu_D-03	
HswPn	>80	Μ	L. guyanensis spp. complex	Not provided	Skin, Arm	Lgu_A-39	
ifG7T	75-79	Μ	L. braziliensis spp. complex	Costa Rica	Skin, Leg	Lbr_B-04	
j5uY1	30-34	Μ	L. braziliensis spp. complex	Bolivia	Mucosa, Nasal	Lbr_A-06	
JD1Fi	35-39	F	L. guyanensis spp. complex	Costa Rica	Skin, Arm	Lgu_A-39	
JfPzu	35-39	Μ	L. guyanensis spp. complex	Not provided	Skin, Face	Lgu_A-39	
JfPzu	35-39	Μ	L. guyanensis spp. complex	Not provided	Skin, Face	Lgu_A-39	
KaEnn	25-29	Μ	L. braziliensis spp. complex	Not provided	Skin, Nose	Lbr_B-04	
L7liP	40-44	Μ	L. braziliensis spp. complex	Guatemala	Skin, Nose	Lbr_C-01	Previously unreported
lqj5v	10-14	F	L. braziliensis spp. complex	Not provided	Mucosa, Nasal	Lbr_A-06	
LY4kh	25-29	F	L. guyanensis spp. complex	Not provided	Skin, Leg	Lgu_A-39	
mj7LX	15-19	F	L. guyanensis spp. complex	Costa Rica	Skin, Knee	Lgu_A-39	
MNaNr	25-29	Μ	L. guyanensis spp. complex	Not provided	Skin, Leg	Lgu_A-39	
MnFJU	20-24	F	L. braziliensis spp. complex	Not provided	Skin, Face	Lbr_J-01	
MQ3Iq	30-34	Μ	L. guyanensis spp. complex	Not provided	Skin, Leg	Lgu_A-39	
MqS1M	< 5	F	L. tropica spp. complex	Not provided	Skin, Face	Ltr_J-01	
N58sC	30-34	Μ	L. braziliensis spp. complex	Not provided	Skin, NOS	Lbr_A-06	

Ngbt9	10-14	F	L. tropica spp. complex	Not provided	Skin, Face	Ltr_F-01	Previously unreported
nhxid	60-64	F	L. braziliensis spp. complex	Not provided	Skin, Face	Lbr_A-06	
nLIzV	5-9	F	L. tropica spp. complex	Yemen	Skin, Nasal	Ltr_D-01	Previously unreported
OkKEs	45-49	F	L. guyanensis spp. complex	Costa Rica	Skin, Leg	Lgu_A-39	
OkKEs	45-49	F	L. guyanensis spp. complex	Costa Rica	Skin, Leg	Lgu_A-39	
oYo7a	40-44	F	L. guyanensis spp. complex	Costa Rica	Skin, Face	Lgu_A-39	
paee2	25-29	U	L. guyanensis spp. complex	Not provided	Skin, NOS	Lgu_B-07	
pmg22	40-44	Μ	L. tropica spp. complex	Tunisia	Skin, Arm	Ltr_G-01	
PRu3I	35-39	Μ	L. guyanensis spp. complex	Costa Rica	Skin, Arm	Lgu_I-01	
PRu3I	35-39	Μ	L. guyanensis spp. complex	Costa Rica	Skin, Ear	Lgu_H-01	Previously unreported
q6Y0m	30-34	F	L. mexicana spp. complex	Belize	Skin, Arm	Lme_A-04	
qljLb	70-74	Μ	L. guyanensis spp. complex	Not provided	Skin, Buccal	Lgu_A-39	
QlW8W	55-59	F	L. guyanensis spp. complex	Not provided	Skin, Arm	Lgu_A-39	
QsNa7	70-74	U	L. mexicana spp. complex	Mexico (Yucatan)	Skin, Arm	Lme_A-04	
QsNa7	70-74	Μ	L. mexicana spp. complex	Mexico (Yucatan)	Skin, Arm	Lme_A-04	
r7Bif	75-79	Μ	L. guyanensis spp. complex	Ecuador	Skin, Ear	Lgu_G-01	Previously unreported
r7Bif	75-79	Μ	Leishmania sp, NOS	Ecuador	Skin, Face	Lsp_A-01	Previously unreported
rHGuZ	35-39	F	L. guyanensis spp. complex	Not provided	Skin, Arm	Lgu_A-39	
rUtEq	10-14	F	L. guyanensis spp. complex	Venezuela	Skin, Leg	Lgu_B-07	
			L. donovani/infantum/chagasi		Lymph Node,		
RZyXs	40-44	Μ	spp. complex	Not provided	inguinal	Ldo_A-01	
SHAjS	25-29	Μ	L. tropica spp. complex	Not provided	Skin, NOS	Ltr_C-01	Previously unreported
SrbZI	35-39	Μ	L. guyanensis spp. complex	Not provided	Skin, Face	Lgu_J-01	
				Multiple endemic			
				countries: Panama			
				OR Honduras OR			
				Nicaragua OR			
				Colombia OR			
tnbbZ	35-39	Μ	L. guyanensis spp. complex	Guatemala	Skin, Hand	Lgu_B-07	

U19Vi	10-14	М	L. guyanensis spp. complex	Not provided	Skin, Hand	Lgu_A-39	
uf2WQ	60-64	F	L. braziliensis spp. complex	Not provided	Skin, Hand	Lbr_I-01	Previously unreported
UMVeK	45-49	M	L. braziliensis spp. complex	Not provided	Mucosa, Tonsil	Lbr_D-01	Treviously unreported
UNIVER	43-49	IVI	L. orazinensis spp. complex		Mucosa, Tonsh	L01_D-01	Reported once, from
UMVeK	45-49	М	L. braziliensis spp. complex	Not provided	Epiglottis	Lbr_H-01	Suriname
UrDnb	45-49	F	L. guyanensis spp. complex	Not provided	Skin, Face	 Lgu_A-39	
usKjM	35-39	F	L. guyanensis spp. complex	Not provided	Skin, Arm	Lgu_A-39	
usKjM	35-39	F	L. guyanensis spp. complex	Not provided	Skin, Hand	Lgu_A-39	
viGq0	70-74	М	L. braziliensis spp. complex	Not provided	Skin, Hand	Lbr_B-04	
VPME3	60-64	Μ	L. mexicana spp. complex	Not provided	Skin, Face	Lme_C-01	
vtbyX	50-54	Μ	L. guyanensis spp. complex	Not provided	Skin, Leg	Lgu_A-39	
VXYJc	35-39	Μ	L. guyanensis spp. complex	Not provided	Skin, NOS	Lgu_A-39	
VXYJc	35-39	Μ	L. guyanensis spp. complex	Not provided	Skin, Arm	Lgu_A-39	
W2523	45-49	F	L. guyanensis spp. complex	Not provided	Skin, Arm	Lgu_K-01	Previously unreported
WdF6F	25-29	Μ	L. major	Not provided	Skin, Leg	Lma_A-01	
wNI9E	40-44	F	L. guyanensis spp. complex	Not provided	Skin, Elbow	Lgu_C-03	Previously unreported
WPNzg	60-64	Μ	L. guyanensis spp. complex	Central America	Skin, Back	Lgu_E-02	
XATsT	5-9	F	L. guyanensis spp. complex	Ecuador	Skin, Arm	Lgu_A-39	
XEnxF	< 5	Μ	L. tropica spp. complex	Not provided	Skin, Face	Ltr_I-01	Previously unreported
				Multiple endemic			
VIGD	50 54			countries: Panama			
XkSqR	50-54	M	L. guyanensis spp. complex	OR Mexico	Skin, Knee	Lgu_B-07	
XpFLs	65-69	Μ	L. mexicana spp. complex	Not provided	Skin, Face	Lme_B-03	
yfxW2	60-64	М	L. braziliensis spp. complex	Not provided	Skin, Arm	Lbr_A-06	
YfZoO	< 5	F	L. guyanensis spp. complex	Not provided	Skin, Knee	Lgu_B-07	
YHq5X	45-49	F	L. tropica spp. complex	Not provided	Skin, Chest	Ltr_E-01	
уqхwб	55-59	F	L. mexicana spp. complex	Not provided	Skin, Leg	Lme_E-01	Previously unreported
YRcvQ	25-29	Μ	L. guyanensis spp. complex	Not provided	Skin, Leg	Lgu_A-39	

				Multiple endemic countries: Central & South America (including			
yv1zu	5-9	F	L. guyanensis spp. complex	Amazon region)	Skin, Arm	Lgu_D-03	
				Not provided	Skin, Arm and		
zDVRa	40-44	Μ	L. major	(suspected)	Flank	Lma_C-01	
zNB0C	20-24	Μ	L. braziliensis	Peru	Skin, Foot	Lbr_G-01	Type 2 L. braziliensis
zOa4f	35-39	F	L. guyanensis spp. complex	Not provided	Skin, Hand	Lgu_A-39	
zr4An	55-59	М	L. guyanensis spp. complex	Costa Rica	Skin, Leg	Lgu_A-39	
zSazm	25-29	F	L. guyanensis spp. complex	Not provided	Skin, Hand	Lgu_A-39	
					Mucosa,		
VmHYS	65-69	Μ	L. braziliensis spp. complex	Guyana	Oropharynx	Lbr_A-06	

<sup>1</sup>Study number is a random 6-digit alphanumeric string which provides a unique, anonymous key for each patient.